Risks of pelvic inflammatory disease and bacterial vaginosis in adenomyosis patients using levonorgestrel intrauterine device or oral norethindrone.

ABSTRACT:

Background

Patients with adenomyosis frequently experience menorrhagia and dysmenorrhea. Levonorgestrel-releasing intrauterine device (LNG-IUD) and oral norethindrone are widely used non-surgical treatment options. However, their associated risks of pelvic inflammatory disease (PID) and bacterial vaginosis (BV) have not been well reported in the previous studies.

Methods

This multi-institutional retrospective analysis was performed using de-identified electronic health records from the TriNetX Research Network. Patients with adenomyosis treated with LNG-IUD or oral norethindrone were identified. A 1:1 propensity score matching (PSM) was conducted to control for potential confounding variables. Subgroup analysis was performed to evaluate the outcomes of the patient group with

SUBMITTER: Niu SY 

PROVIDER: S-EPMC12702703 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature